{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:35:39Z","timestamp":1791498939917,"version":"4.3.4"},"reference-count":35,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Mantle cell lymphoma (MCL) predominantly affects older adults, and treatment options for relapsed\/refractory (R\/R) disease remain limited. Brexucabtagene autoleucel (brexu-cel) has demonstrated high efficacy in R\/R MCL, but data in older adult populations are scarce. This retrospective, real-world analysis evaluated patients aged \u226570 years with R\/R MCL treated with brexu-cel and reported to the EBMT registry between 2020 and 2024. A total of 233 patients from 96 centers across 13 countries were included (median age at infusion, 74.6 years; 44% &amp;gt;75 years). Most had Eastern Cooperative Oncology Group (ECOG) 0 to 1 (89%) and were heavily pretreated; 62% had prior Bruton tyrosine kinase inhibitor exposure. At day +100, the best overall response was complete remission in 78% and partial remission in 13%. At 30 days, the cumulative incidence of any-grade cytokine release syndrome was 80% (grade \u22653, 9%) and immune effector cell\u2013associated neurotoxicity syndrome was 57% (grade \u22653, 22%). At 1 year, overall survival (OS) was 74%; progression-free survival (PFS), 62%; relapse\/progression incidence, 25%; and nonrelapse mortality (NRM), 13%. Patients aged &amp;gt;75 years had outcomes comparable with those aged 70 to 75 years. In multivariable analysis, ECOG \u22652 remained the strongest predictor of inferior OS (hazard ratio [HR], 4.50; P&amp;lt; .001) and PFS (HR, 3.10; P&amp;lt; .001), whereas age was not independently associated with outcomes. Brexu-cel is effective in patients aged \u226570 years with R\/R MCL, achieving high remission rates and meaningful survival, despite a relatively high incidence of NRM. Functional status, rather than age, should guide eligibility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019367","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T20:54:51Z","timestamp":1772657691000},"page":"3135-3142","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of patients over 70 years treated with brexu-cel for R\/R mantle cell lymphoma: a study from the CTIWP of EBMT"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-8084","authenticated-orcid":false,"given":"Nicole","family":"Santoro","sequence":"first","affiliation":[{"name":"1Hematology Unit, Department of Oncology and Hematology, Pescara Hospital, Pescara, Italy"},{"name":"2Department of Medicine and Aging Sciences, University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5504-2935","authenticated-orcid":false,"given":"Jarl Edouard","family":"Mooyaart","sequence":"additional","affiliation":[{"name":"3European Society for Blood and Marrow Transplantation Leiden Study Unit, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Protheroe","sequence":"additional","affiliation":[{"name":"5Bristol Haematology Unit, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[{"name":"6Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Oncology, and Rheumatology, University Clinic Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van Meerten","sequence":"additional","affiliation":[{"name":"8Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"},{"name":"9Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankara","family":"Paneesha","sequence":"additional","affiliation":[{"name":"10University Hospital Birmingham NHS Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-2833","authenticated-orcid":false,"given":"Robin","family":"Sanderson","sequence":"additional","affiliation":[{"name":"11Department of Hematology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8683-6930","authenticated-orcid":false,"given":"Ron","family":"Ram","sequence":"additional","affiliation":[{"name":"12Bone Marrow Transplant Unit, Tel Aviv Sourasky Medical Center and Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Northend","sequence":"additional","affiliation":[{"name":"13University College London Hospitals NHS Foundation Trust, London, UK; Cancer Research UK & UCL Cancer Trials Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":false,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[{"name":"14Service d\u2019H\u00e9matologie Clinique et Th\u00e9rapie Cellulaire, CHU Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-6198","authenticated-orcid":false,"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[{"name":"15Department of Hematology and Bone Marrow Transplantation, CHU Toulouse, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[{"name":"16Centre Hospitalier Universitaire de Lille, University of Lille, INSERM U1286, Infinite, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorinde Desiree","family":"Hoogenboom","sequence":"additional","affiliation":[{"name":"3European Society for Blood and Marrow Transplantation Leiden Study Unit, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0826-9498","authenticated-orcid":false,"given":"Maiana Hamdan Melo","family":"Coelho","sequence":"additional","affiliation":[{"name":"17Laborat\u00f3rio Investiga\u00e7\u00e3o M\u00e9dica 31, Hospital das Clinicas, Faculty of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4688-2478","authenticated-orcid":false,"given":"Simona","family":"Pagliuca","sequence":"additional","affiliation":[{"name":"18Hematology Department, Nancy University Hospital, Vandoeuvre-l\u00e8s-Nancy, France"},{"name":"19Universit\u00e9 de Lorraine, Centre National de la Recherche Scientifique, Unit\u00e9 Mixte de Recherche 7365, Ing\u00e9nierie Mol\u00e9culaire et Physiopathologie Articulaire, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Malard","sequence":"additional","affiliation":[{"name":"20Sorbonne Universit\u00e9, Centre de Recherche Saint-Antoine INSERM UMRs 938, Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, Assistance Publique - H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3914-7806","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Kuball","sequence":"additional","affiliation":[{"name":"21Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"22Catalan Institute of Oncology, Duran Reynals Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"23Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"24Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-619X","authenticated-orcid":false,"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[{"name":"17Laborat\u00f3rio Investiga\u00e7\u00e3o M\u00e9dica 31, Hospital das Clinicas, Faculty of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"26","key":"2026050815183122300_bib1","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2026050815183122300_bib2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"2026050815183122300_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"2026050815183122300_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5045\/br.2023.2023208","article-title":"A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma","volume":"58","author":"Lee","year":"2023","journal-title":"Blood Res"},{"issue":"3","key":"2026050815183122300_bib5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/10428194.2024.2431563","article-title":"Challenges of treating mantle cell lymphoma in older adults","volume":"66","author":"Mu\u00f1oz","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"10441","key":"2026050815183122300_bib6","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"issue":"14","key":"2026050815183122300_bib7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2026050815183122300_bib8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026050815183122300_bib9","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1080\/10428194.2023.2212098","article-title":"A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed\/refractory mantle cell lymphoma","volume":"64","author":"Banerjee","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2026050815183122300_bib10","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2026050815183122300_bib11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.19037","article-title":"Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement","volume":"203","author":"Ryan","year":"2023","journal-title":"Br J Haematol"},{"issue":"14","key":"2026050815183122300_bib12","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050815183122300_bib13","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1097\/01.HS9.0000848672.43673.8a","article-title":"Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for the treatment of relapsed or refractory (R\/R) mantle cell lymphoma (MCL) in the United States (US) [abstract]","volume":"6","author":"Locke","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2026050815183122300_bib14","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1182\/blood-2023-182415","article-title":"Real world results of brexucabtagene autoleucel for patients with relapsed\/refractory mantle cell lymphoma - first German\/Swiss analysis","volume":"142","author":"Hess","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026050815183122300_bib15","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2026050815183122300_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/blood-2023-174273","article-title":"Outcomes of patients with relapsed\/refractory mantle cell lymphoma (R\/R MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 and ZUMA-18, an expanded access study","volume":"142","author":"Goy","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2026050815183122300_bib17","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2023012255","article-title":"CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"2026050815183122300_bib18","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1002\/hem3.87","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real-world intention-to-treat analysis","volume":"8","author":"O\u2019Reilly","year":"2024","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2026050815183122300_bib19","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/blood-2021-153277","article-title":"Analysis of outcomes and predictors of response in patients with relapsed mantle cell lymphoma treated with brexucabtagene autoleucel","volume":"138","author":"Romancik","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2026050815183122300_bib20","first-page":"3745","article-title":"Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry","volume":"109","author":"Herbaux","year":"2024","journal-title":"Haematol"},{"issue":"suppl 16","key":"2026050815183122300_bib21","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2023.41.16_suppl.7507","article-title":"Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R\/R) mantle cell lymphoma (MCL): a CIBMTR subgroup analysis by prior treatment","volume":"41","author":"Kambhampati","year":"2023","journal-title":"JCO"},{"issue":"20","key":"2026050815183122300_bib22","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1182\/bloodadvances.2024015014","article-title":"Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis","volume":"9","author":"Ahmed","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026050815183122300_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"27","key":"2026050815183122300_bib24","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"JCO"},{"key":"2026050815183122300_bib25","unstructured":"US Department of Health and Human Services\n          . Common Terminology Criteria for Adverse Events (CTCAE). V4.03. Accessed 11 March 2026. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf."},{"issue":"1","key":"2026050815183122300_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2026050815183122300_bib27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2026050815183122300_bib28","doi-asserted-by":"crossref","first-page":"100670","DOI":"10.1016\/j.blre.2020.100670","article-title":"Older adults in hematologic malignancy trials: representation, barriers to participation and strategies for addressing underrepresentation","volume":"43","author":"Kanapuru","year":"2020","journal-title":"Blood Rev"},{"issue":"1","key":"2026050815183122300_bib29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/annonc\/mdr035","article-title":"Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT)","volume":"23","author":"Jantunen","year":"2012","journal-title":"Ann Oncol"},{"issue":"7","key":"2026050815183122300_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00432-025-06249-z","article-title":"Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"151","author":"Schleifenbaum","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"2026050815183122300_bib31","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"issue":"14","key":"2026050815183122300_bib32","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1182\/bloodadvances.2024012727","article-title":"Optimization of older adults by a geriatric assessment\u2013guided multidisciplinary clinic before CAR T-cell therapy","volume":"8","author":"Yates","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2026050815183122300_bib33","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41409-025-02541-1","article-title":"Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study","volume":"60","author":"Kharfan-Dabaja","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"suppl 1","key":"2026050815183122300_bib34","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2024-203370","article-title":"Real world outcomes with evolving management of cytokine release syndrome in CAR-T therapy","volume":"144","author":"Bansal","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026050815183122300_bib35","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3135\/2516202\/blooda_adv-2025-019367-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3135\/2516202\/blooda_adv-2025-019367-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:18:41Z","timestamp":1778267921000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3135\/566928\/Outcomes-of-patients-over-70-years-treated-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019367","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,5,1]]}}}